Annual Meeting Press Program

ASH is pleased to offer credentialed media the following 60-minute press briefings. All briefings will include thematic overviews, brief presentations by each of the press presenters, and live Q&A. Please note the embargo times indicated. 

On-site and virtual briefings

Sickle Cell Disease: From Discovery to Access 

Moderator: Titilope Fasipe, MD, PhD
Briefing time: Wednesday, December 3 at 12:00 p.m. ET (Virtual)
Embargo lift time: Saturday, December 6 at 7:00 a.m. ET

• 2: Outcomes of pregnancies in sickle cell patients treated with hydroxyurea: Findings from the escort-HU cohort studies  
• 379: First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises 
• 1051: Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis
• 121: Multicenter evaluation of guideline adherence for the timeliness of pain medication for acute sickle cell disease pain
• 277: Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia

More Than Medicine: Improving Patient Experience and Access  

Moderator: Adam Cuker, MD, MS
Briefing time: Saturday, December 6 at 7:15 a.m. ET
Embargo lift time: Saturday, December 6 at 7:15 a.m. ET

• 5: Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections 
• 595: Implementation of a multidisciplinary quality improvement project standardizing an approach to screening and treating iron deficiency in pregnancy 
• 710: Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial 
• 290: Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles  

The Next Wave of Innovation: Breakthrough Blood Cancer Trial Findings 

Moderator: Wendy Stock, MD
Briefing time: Saturday, December 6 at 8:30 a.m. ET
Embargo lift time: Saturday, December 6 at 8:30 a.m. ET

• 1: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial 
• 343: Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials 
• 163: High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)  
• 936: Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Emerging Therapies and Immunotherapies in Blood Cancers

Moderator: Laura Michaelis, MD
Briefing time: Sunday, December 7 at 7:30 a.m. ET
Embargo lift time: Sunday, December 7 at 7:30 a.m. ET

• 6: Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia 
• 466: Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma 
• 683: Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
• 439: First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients 

Late-Breaking Abstracts Press Briefing

Moderator: Surbhi Sidana, MD
Briefing time: Monday, December 8 at 8:00 a.m. ET
Embargo lift time: Tuesday, December 9 at 7:30 a.m. ET

• LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
• LBA-3: Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
• LBA-5: A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial
• LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3